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Abstract
Molecular agents targeting the epidermal growth factor receptor (EGFR)- , anaplastic 
lymphoma kinase (ALK)- or c- ros oncogene 1 (ROS1) alterations have revolutionized 
the treatment of oncogene- driven non- small- cell lung cancer (NSCLC). However, 
the emergence of acquired resistance remains a significant challenge, limiting the 
wider clinical success of these molecular targeted therapies. In this study, we inves-
tigated the efficacy of various molecular targeted agents, including erlotinib, alec-
tinib, and crizotinib, combined with anti- vascular endothelial growth factor receptor 
(VEGFR) 2 therapy. The combination of VEGFR2 blockade with molecular targeted 
agents enhanced the anti- tumor effects of these agents in xenograft mouse models 
of EGFR- , ALK- , or ROS1- altered NSCLC. The numbers of CD31- positive blood vessels 
were significantly lower in the tumors of mice treated with an anti- VEGFR2 antibody 
combined with molecular targeted agents compared with in those of mice treated 
with molecular targeted agents alone, implying the antiangiogenic effects of VEGFR2 
blockade. Additionally, the combination therapies exerted more potent antiprolif-
erative effects in vitro in EGFR- , ALK- , or ROS1- altered NSCLC cells, implying that 
VEGFR2 inhibition also has direct anti- tumor effects on cancer cells. Furthermore, 
VEGFR2 expression was induced following exposure to molecular targeted agents, 
implying the importance of VEGFR2 signaling in NSCLC patients undergoing mo-
lecular targeted therapy. In conclusion, VEGFR2 inhibition enhanced the anti- tumor 
effects of molecular targeted agents in various oncogene- driven NSCLC models, 
not only by inhibiting tumor angiogenesis but also by exerting direct antiprolifera-
tive effects on cancer cells. Hence, combination therapy with anti- VEGFR2 antibod-
ies and molecular targeted agents could serve as a promising treatment strategy for 
oncogene- driven NSCLC.
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1  | INTRODUC TION
The identification of oncogenic gene alterations has revolutionized 
the treatment of advanced non- small- cell lung cancer (NSCLC). 
Mutations in epidermal growth factor receptor (EGFR),1 anaplastic 
lymphoma kinase (ALK),2 and c- ros oncogene 1 (ROS1) genes3 are 
among the most common oncogenic alterations in NSCLC,4 and 
agents targeting these mutated proteins have been shown to exert 
strong anti- tumor effects.5- 7 However, a significant percentage of 
patients develop acquired resistance to these agents, hence the de-
velopment of combination therapies is of high clinical importance.
Antiangiogenic agents suppress tumor growth by inhibiting the 
formation of new blood vessels.8 The vascular endothelial growth 
factor (VEGF)- targeting antibody bevacizumab has been proven ef-
fective in combination with cytotoxic chemotherapy in patients with 
advanced NSCLC.9 Moreover, the combination of bevacizumab with 
EGFR tyrosine kinase inhibitors (TKIs) exerted strong anti- tumor ef-
fects in EGFR- mutant NSCLC.10 Notably, patients treated with the 
EGFR- TKI erlotinib plus bevacizumab had a median progression- free 
survival of 16.9 mo, compared with 13.3 mo in patients treated with 
erlotinib alone.10 Similarly, combination of the anti- VEGFR2 antibody 
ramucirumab with erlotinib significantly prolonged the progression- 
free survival of patients with EGFR- mutant NSCLC compared with 
erlotinib alone (19.4 vs. 12.4 mo, P < .0001).11 Although these data 
imply that targeting the VEGF pathway augments the anti- tumor 
effects of EGFR TKIs, the underlying mechanisms remain unclear. 
Furthermore, whether the combination of anti- VEGFR2 therapy 
with other targeted molecular therapies provides a clinical benefit 
in patients with oncogene- driven NSCLC remains to be elucidated.
In this study, we investigated the therapeutic effects of anti- 
VEGFR2 therapy in combination with different molecular targeted 
agents in oncogene- driven NSCLC, as well as explored the mecha-
nisms underlying the synergistic effects of these therapies.
2  | MATERIAL S AND METHODS
2.1 | Cell lines and reagents
PC- 9 cells (EGFR Ex19 del E746_A750) were purchased from the 
European Collection of Authenticated Cell Cultures and A549 cells 
from the American Type Culture Collection. H3255 cells were kindly 
gifted by N Fujimoto and JM Kurie (MD Anderson Cancer Center, 
Houston, TX, USA). H3122 (EML4- ALK fusion) and HCC78 (SLC34A2- 
ROS1 fusion) cells were kindly provided by William Pao (Vanderbilt 
University, Nashville, TN, USA). ABC- 11 (EML4- ALK fusion) and ABC- 
20 (CD74- ROS1 fusion) cells were established from NSCLC patients 
in our laboratory.12,13 All cell lines were cultured in RPMI- 1640 me-
dium (Sigma- Aldrich) supplemented with 10% heat- inactivated fetal 
bovine serum and 1% penicillin/streptomycin; cells were maintained 
at 37°C in a 5% CO2 humified atmosphere.
Ramucirumab and the anti- mouse VEGFR2 antibody DC101 
were obtained from Eli Lilly. Erlotinib, osimertinib, alectinib, and 
crizotinib were purchased from Selleck Chemicals. All compounds 
were dissolved in dimethyl sulfoxide for in vitro studies.
Growth inhibition was measured using the modified 3- (4,5- di
methylthiazol- 2- yl)- 2,5- diphenyltetrazolium bromide (MTT) assay. 
Briefly, cells were seeded into 96- well plates at densities of 1000- 
8000 cells/well (PC- 9:1000 cells/well; H3255/ABC- 11/H3122: 
3000 cells/well; HCC78: 2000 cells/well; ABC- 20:8000 cells/well) 
and treated with each drug for 96 h.
2.2 | Antibodies, immunoblotting, and receptor 
tyrosine kinase array
The following antibodies were obtained from Cell Signaling 
Technology: phospho- EGFR (Tyr1068), EGFR, phospho- ALK 
(Tyr1282/1283), ALK, phospho- ROS1 (Tyr2274), ROS1, phospho- 
ERK1/2 (Thr202/Tyr204), ERK1/2, phospho- AKT (Ser473), AKT, 
GAPDH, and horseradish peroxidase- conjugated anti- rabbit IgG 
antibody.
For immunoblotting, cells were harvested, washed in phosphate- 
buffered saline, and lysed in radioimmunoprecipitation assay buffer 
(1% Triton X- 100, 0.1% sodium dodecyl sulfate, 50 mmol/L Tris- 
HCl, pH 7.4, 150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 
10 mmol/L β- glycerol- phosphate, 10 mmol/L NaF, and 1 mmol/L so-
dium orthovanadate) containing a protease inhibitor cocktail (Roche 
Applied Sciences). Proteins were separated by sodium dodecyl 
sulfate– polyacrylamide gel electrophoresis and then transferred 
onto membranes, which were then incubated with the indicated pri-
mary and secondary antibodies. Chemiluminescence was detected 
using an enhanced chemiluminescence plus reagent (GE Healthcare 
Biosciences).
Phospho- receptor tyrosine kinase arrays were performed using 
a phospho- receptor tyrosine kinase array kit (R&D Systems) in ac-
cordance with the manufacturer's instructions. Bands and dots were 
detected using the ImageQuant LAS- 4000 imager (GE Healthcare 
Biosciences).
2.3 | Immunohistochemistry
Formalin- fixed, paraffin- embedded tissue blocks were cut into 
5- μm- thick sections, placed on glass slides, and deparaffinized with 
d- limonene and graded alcohols. Antigen retrieval was performed by 
incubating the sections in 10 mmol/L sodium citrate buffer (pH 6.0) for 
10 min at 95°C. Subsequently, the sections were incubated for 10 min 
in methanol containing 3% hydrogen peroxide to block endogenous 
peroxidase activity. After washing with Tris- buffered saline containing 
0.1% Tween 20, tissues were incubated with normal goat serum for 
60 min. Sections were probed with an anti- CD31 antibody (#77699; 
Cell Signaling Technology) and anti- VEGFR2 antibody(#2479S; Cell 
Signaling Technology) overnight at 4°C. Thereafter, the sections were 
incubated for 30 min with biotinylated anti- rabbit antibodies and 
avidin- biotinylated horseradish peroxidase conjugate (SignalStain 
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Boost IHC Detection Reagent #8114; Cell Signaling Technology). 
Finally, sections were incubated with 3,3- diaminobenzidine and coun-
terstained with hematoxylin. The antibody dilutions were performed in 
accordance with the manufacturer's instructions.
2.4 | Quantitative reverse- transcription polymerase 
chain reaction (qRT- PCR)
RNA was extracted from cells using the RNeasy Mini Kit (Qiagen) 
in accordance with the manufacturer's instructions. VEGFR2 copy 
number gain was assessed by qRT- PCR using the TaqMan probes 
and primers detailed in Table S1. PCR was run on the LightCycler 
Real- Time PCR System (Roche Applied Science), and gene dosage 
was calculated using a standard curve. The VEGFR2/GAPDH copy 
number ratio was also calculated.
2.5 | Small interfering RNA (siRNA) transfection
Transfection conditions for siRNA- mediated gene knockdown were 
optimized using VEGFR2 siRNAs (Dharmacon Inc) and Lipofectamine 
Transfection Reagent (Thermo Fisher Scientific) in a 96- well plate 
format (PC- 9:1500 cells/well; H3122: 3000 cells/well; ABC- 
20:8000 cells/well). Two predesigned gene- specific siRNAs were 
tested for each candidate gene, along with negative and positive 
controls (Dharmacon VEGFR2 siRNA). Gene silencing efficiency was 
evaluated 48 h post- transfection by qRT- PCR.
2.6 | ELISA
Cells were seeded into 3.5 cm cell culture dishes (3.0 × 105 cells/
dish), and the cell supernatant was collected after 24 h. The levels of 
VEGF- A were determined by Human VEGF Quantikine ELISA (R&D 
Systems) in accordance with the manufacturer's instructions.
2.7 | Xenograft mouse models
Female BALB/c nu/nu mice (6 wk old) were purchased from Charles 
River Laboratories). All mice were provided sterilized food and water 
and housed in a barrier facility under a 12- h light/dark cycle. Cancer 
cells (2- 5 × 106) were injected subcutaneously into the back on 
both sides of the mice. When the average tumor volume reached 
~200 mm3, the mice were randomly allocated into 4 treatment 
groups (4 mice/group): vehicle, DC101 (10 mg/kg/d), molecular tar-
geted agent (erlotinib [30 mg/kg/d], osimertinib [5 mg/kg/d], alec-
tinib [10 mg/kg/d], or crizotinib [50 mg/kg/d]), and DC101 combined 
with the molecular targeted agents. Vehicle and molecular targeted 
agents were administered by gavage once daily, 5 times weekly. 
DC101 was administered by intraperitoneal administration once 
daily, twice weekly.
Tumor volume (width2 × length/2) was determined periodically. 
Statistical analyses were conducted using the tumor volumes mea-
sured on day 28. All experiments involving animals were performed 
under the auspices of the Institutional Animal Care and Research 
Advisory Committee at the Department of Animal Resources, 
Okayama University Advanced Science Research. The exper-
iments were performed under the Policy on the Care and Use of 
the Laboratory Animals, Okayama University, and Fundamental 
Guidelines for Proper Conduct of Animal Experiment and Related 
Activities in Academic Research Institutions, Ministry of Education, 
Culture, Sports, Science and Technology of Japan. The experimental 
protocol was approved by the Animal Care and Use Committee of 
the Okayama University, Okayama, Japan (OKU- 2018455).
2.8 | Statistical analysis
Statistical analysis was performed using STATA software (version 
15; StataCorp). Differences between groups were compared using 
two- tailed paired Student t tests. P- values < .05 were considered 
statistically significant.
3  | RESULTS
3.1 | Anti- VEGFR2 therapy augments the efficacy 
of molecular targeted therapy in oncogene- driven 
cancer
Here, we investigated the effects of the anti- mouse VEGFR2 an-
tibody DC101 on the efficacy of molecular targeted therapies in 
NSCLC harboring EGFR, ALK, or ROS1 alterations. To this end, we 
used the EGFR- mutant PC- 9 and H3255 cells, the ALK- rearranged 
H3122 and ABC- 11 cells, and the ROS1- rearranged ABC- 20 cells. We 
first assessed the efficacy of DC101 on erlotinib in PC- 9 xenograft 
tumors, which harbor an EGFR exon 19 deletion. DC101 and erlo-
tinib combination therapy exerted more potent anti- tumor effects 
compared with erlotinib monotherapy (Figure 1A). We also assessed 
the combination therapy in H3255 xenograft tumors harboring the 
EGFR exon 21 L858R point mutation. Both erlotinib monotherapy 
and the combination of DC101 with erlotinib almost completely in-
hibited tumor growth up to 60 d of treatment. Tumor regrowth was 
observed in the erlotinib monotherapy group after cessation of the 
treatment, whereas more durable tumor inhibition was observed in 
the combination therapy group (Figure 1B).
The efficacy of the combination of DC101 with EGFR TKIs was 
also investigated using osimertinib, a third- generation EGFR- TKI. 
The combination therapy provided significantly stronger anti- 
tumor effects in PC- 9 xenograft tumors compared with osimerti-
nib alone (Figure S1A). Similarly, the combination of DC101 with 
the ALK- TKI alectinib exerted stronger anti- tumor effects in ALK- 
rearranged H3122 tumors compared with alectinib monotherapy 
(Figure 1C). Similar results were obtained with ALK- rearranged 
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ABC- 11 xenograft models, in which treatment with DC101 aug-
mented the therapeutic effects of alectinib (Figure 1D). We 
also investigated the therapeutic effects of DC101 in ROS1- 
rearranged NSCLC using ABC- 20 cells (CD74- ROS1 fusion). DC101 
significantly enhanced the anti- tumor effects of the ROS1- TKI 
crizotinib in ABC- 20 tumors (Figure 1E). Notably, no significant 
toxicities were observed in mice treated with any of the combi-
nation therapies (Figures S1B and S2). ROS1- rearranged HCC78 
F I G U R E  1   Combination of molecular targeted agents and VEGFR2 blockade in xenograft mouse models. Mice were transplanted with 
PC- 9, H3255, H3122, ABC- 11, or ABC- 20 cells. Molecular targeted agents were orally administered 5 times weekly. DC101 was administered 
intraperitoneally (10 mg/kg/d) twice weekly. A, B, Mice bearing PC- 9 or H3255 tumors were treated with vehicle, erlotinib (30 mg/kg/d), 
DC101, or erlotinib plus DC101 combination. In H3255- transplanted mice, the erlotinib dose was reduced to 15 mg/kg/d from day 21, and 
the treatment was discontinued from day 53. C, D, Mice bearing H3122 and ABC- 11 tumors were treated with vehicle, alectinib (10 mg/
kg/d), DC101, or alectinib plus DC101 combination. E, Mice bearing ABC- 20 tumors were treated with vehicle, crizotinib (50 mg/kg/d), 
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cells failed to engraft even in highly immunosuppressed NOG mice 
(data not shown).
3.2 | Combination of anti- VEGFR2 antibody 
with molecular targeted therapy inhibits tumor 
angiogenesis
To elucidate the mechanisms underlying the enhanced anti- tumor ef-
fects of the combination of DC101 with molecular targeted therapy, 
we analyzed the extent of tumor angiogenesis in xenograft tumors. 
Anti- mouse CD- 31 antibody stained the vessels, but anti- human 
CD- 31 antibody did not (data not shown), suggesting that the tumor 
vessels were derived from mouse tissues. Anti- mouse CD31 immu-
nostaining revealed that DC101 monotherapy or the combination 
of DC101 with erlotinib, alectinib, or crizotinib impaired angiogen-
esis in PC- 9 (EGFR- mutant), H3122 (ALK- rearranged), and ABC- 20 
(ROS1- rearranged) xenograft tumors, respectively (Figures 2A and 
S1C). The combination treatments provided more profound an-
tiangiogenic effects compared with the molecular targeted agents 
alone (Figures 2B,C and S1D), although quantification could not be 
performed in PC- 9 tumors due to their small size. These data imply 
that DC101 enhanced the anti- tumor effects of molecular targeted 
agents by inhibiting tumor angiogenesis.
3.3 | VEGFR2 blockade 
enhances the antiproliferative effects of molecular 
targeted therapies in vitro
To determine whether VEGFR2 inhibition has any impact on oncogene- 
driven NSCLC cells themselves in addition to inhibiting tumor angio-
genesis, we investigated the effects of VEGFR2 blockade in different 
NSCLC cell lines in vitro. As all of the cell lines used were derived from 
human NSCLC, we used the human anti- VEGFR2 antibody ramu-
cirumab. We performed cell proliferation assays in EGFR- mutant (PC- 
9, H3255), ALK- rearranged (ABC- 11, H3122), and ROS- 1- rearranged 
(ABC- 20, HCC78) NSCLC cells treated with erlotinib, alectinib, and 
crizotinib, respectively (Figure 3A,B). Although the difference was 
moderate, combination with ramucirumab significantly enhanced their 
antiproliferative effects in vitro, implying a potential role of VEGFR2 
signaling in NSCLC cell proliferation. We also assessed the effects of 
F I G U R E  2   VEGFR2 blockade 
suppresses angiogenesis in xenograft 
mouse models. A, Immunohistochemical 
staining of CD31 in PC- 9, H3122, and 
ABC- 20 xenograft tumors. Scale bars: 
100 μm. B, C, Number of CD31- positive 
blood vessels in tumors treated with the 
indicated drugs. Each bar indicates the 
average number of CD31- positive blood 
vessels in 5 fields. Error bars represent 





























































6  |     WATANABE ET Al.
siRNA- mediated VEGFR2 silencing combined with molecular targeted 
agents (Figure 4). Consistently, VEGFR2 silencing significantly en-
hanced the antiproliferative effects of molecular targeted agents in 
PC- 9, H3122, and ABC- 20 cells (Figure 4A- C). Decreased VEGFR2 ex-
pression by siVEGFR2 was confirmed in all of these cells (Figure 4D- F).
We then investigated the effects of VEGFR2 inhibition on down-
stream signaling pathways. We found that cells treated with the 
combination therapies had lower phospho- ERK1/2 and phospho- 
AKT levels than did cells treated with molecular targeted agents 
alone in PC- 9, H3122, and ABC- 20 cells (Figure 4G- I). These findings 
imply that VEGFR2 signaling is involved in upstream AKT and ERK 
pathways in oncogene- driven NSCLC, and that anti- VEGFR2 ther-
apy, in addition to exerting antiangiogenic effects, could provide 
strong cell- intrinsic anti- tumor effects by interfering with various 
oncogenic pathways.
3.4 | VEGF- A and VEGFR2 are highly expressed in 
oncogene- driven NSCLC cells
To investigate the relationship between oncogenic pathways and 
VEGFR2 activation, we assessed the level of VEGF- A, a VEGFR2 
F I G U R E  3   VEGFR2 blockade 
enhances the antiproliferative effects of 
molecular targeted therapies in vitro. A, 
Cell proliferation assays in cells treated 
with the indicated concentrations 
of each molecular targeted agent. 
Ramucirumab was used at 150 μg/
mL. All experiments were performed in 
triplicate, and representative data are 
shown. B, Antiproliferative effects of 
the combination therapy with erlotinib 
(100 nmol/L), alectinib (100 nmol/L), and 
ramucirumab (150 μg/mL) in PC- 9 and 
H3122 cells over 96 h, as determined 
by MTT assay. Data are presented as 
means ± SE. *P < .001
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F I G U R E  4   Effects of VEGFR2 silencing combined with molecular targeted agents on oncogenic signaling pathways and cell growth. A- C, Two 
different VEGFR2- targeting siRNAs were used. The effects of VEGFR2 silencing on cell growth in PC- 9, H3122, and ABC- 20 cells. PC- 9 cells were 
treated with erlotinib (100 nmol/L) for 96 h, H3122 cells with alectinib (100 nmol/L) for 96 h, and ABC- 20 cells with crizotinib (1 μmol/L) for 96 h. 
All cell lines were treated with ramucirumab (150 μg/mL) for 96 h. *P < .005. D- F, qRT- PCR analysis showing efficient siRNA- mediated VEGFR2 
knockdown in different cell lines. GAPDH was used as the reference gene. Data are presented as means ± SE. G- I, Phospho- ERK1/2 (PC- 9 and 
ABC- 20 cells) and phospho- AKT levels (H3122 cells) were lower in cells treated with the combination therapy compared with in cells treated 
with the molecular targeted agents alone. PC- 9, H3122, and ABC- 20 cells were treated with erlotinib (100 nmol/L), alectinib (100 nmol/L), and 


































8  |     WATANABE ET Al.
ligand, in the cell culture supernatant of oncogene- driven NSCLC 
cells. A549 and H2009 cells, both of which are wild- type for EGFR, 
ALK, and ROS- 1, were used as controls. The majority of cell lines 
harboring EGFR, ALK, or ROS1 alteration exhibited higher VEGF- A 
protein levels compared with control A549 cells (Figure 5A). We 
also found that HEK293T cells expressing mutant EGFR (L858R or 
exon 19 deletion) had significantly higher VEGF- A protein levels 
in the cell supernatant compared with control cells (Figure 5B), 
implying that VEGF- A secretion was driven by oncogenic signal-
ing. Notably, treatment with erlotinib, alectinib, or crizotinib sig-
nificantly decreased VEGF- A secretion (Figure 5C), confirming 
that VEGF- A production was driven by oncogenic signaling. Of 
note, long- term exposure to molecular targeted agents further 
increased VEGF- A secretion, indicating that VEGF- A would be 
F I G U R E  5   VEGF- A is highly expressed in oncogene- driven NSCLC cells. Cells were seeded into 3.5 cm dishes at 3.0 × 105 cells/2.0 mL, 
and the cell culture supernatant was collected after 24 h. A, The cell supernatant of EGFR- , ALK- , or ROS1- altered cell lines (H3255, ABC- 11, 
H3122, HCC78, and ABC- 20) contained higher VEGF- A levels compared with that of A549 control cells. B, HEK293T cells transfected with 
mutant EGFR (L858R or exon 19 deletion) exhibited higher levels of VEGF- A secretion compared with control cells. C, VEGF- A secretion 
after treatment with molecular targeted agents. PC- 9, ABC- 11, and ABC- 20 cells were treated with erlotinib (100 nmol/L), alectinib 
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more important under long- term inhibition of oncogene signal in-
hibition. A cell proliferation assay at the time of VEGF- A recov-
ery (after 6 wk of treatment) revealed early emergence of cellular 
acquired resistance, suggesting that VEGF- A recovery occurred 
after such resistance developed (Figure S3).
We also assessed VEGFR2 expression at the mRNA level using 
qRT- PCR VEGFR2 mRNA levels were significantly higher in EGFR- , 
ALK- , or ROS1- altered cells (PC- 9, H3255, ABC- 11, H3122, HCC78, 
and ABC- 20) compared with control cells (A549 and H2009; 
Figure 6A). We next investigated the VEGFR2 expression levels in 
clinical samples of EGFR- mutant NSCLCs. VEGFR2 was expressed in 
3 out of 4 lung cancers with EGFR mutations, although no expression 
was found in the 2 EGFR/ALK/ROS1 wild- type NSCLCs (Figure 6B). 
Those data imply a potential role for VEGFR2 signaling in EGFR/ALK/
ROS1- driven NSCLC. Of note, treatment with erlotinib, alectinib, or 
crizotinib significantly increased the VEGFR2 mRNA level in EGFR- 
(PC- 9, H3255), ALK- (ABC- 11, H3122), or ROS1- altered (ABC- 20, 
HCC78) NSCLC cells, respectively (Figure 6C). These findings imply 
that VEGF- A/VEGFR2 signaling in oncogene- driven NSCLC might 
be more critical under oncogene signal inhibition. Finally, we deter-
mined the VEGFR2 expression levels of the HEK293T model with or 
without mutant EGFR transfection (Figure S4). Unexpectedly, 19del 
or L858R transfection decreased VEGFR2 expression in HEK293T 
cells. Although the precise reason for this discrepancy from the data 
shown in Figure 6A,B remains unclear, forced expression may not 
simulate accurately the condition of EGFR- mutant lung cancer cells.
3.5 | VEGFR2 blockade augments the anti- tumor 
effects of TKIs by acting on both tumor cells and 
tumor vessels
In the human body, anti- human VEGFR2 therapy works on both 
cancer cells and micro- environmental tumor vessels. However, in 
our xenograft mouse model, the anti- human VEGFR2 antibody ra-
mucirumab acted only on xenograft tumors, while the anti- mouse 
VEGFR2 antibody DC101 acted only on the vessels. Hence, to tar-
get VEGFR2 on both cancer cells and tumor vessels, we treated 
PC- 9 xenograft tumors with both ramucirumab and DC101. We 
found that the combination of erlotinib, DC101, and ramucirumab 
provided the most potent anti- tumor effects in the xenograft 
mouse model (Figure 7A), with no significant toxicity (Figure 7B). 
Importantly, CD31 immunostaining revealed that the combination 
of DC101 and erlotinib or the triplet combination of DC101, ra-
mucirumab, and erlotinib strongly inhibited vessels in the tumors 
treated (Figure 7C,D).
4  | DISCUSSION
In this study, we demonstrated that VEGFR2 blockade augmented 
the anti- tumor effects of molecular targeted agents in various 
oncogene- driven NSCLCs harboring EGFR, ALK, or ROS1 alterations. 
The enhanced anti- tumor effects of the combination therapy were 
mediated via direct inhibition of cancer cell growth, as well as an-
tiangiogenic effects. We previously showed that bevacizumab, an 
anti- VEGF- A antibody, enhanced the effects of EGFR TKIs in EGFR- 
mutant NSCLC.14- 16 However, the effects of VEGFR2 blockade on 
the efficacy of EGFR TKIs or other molecular targeted agents in 
NSCLC were unclear. Therefore, in this study, we expanded our find-
ings on the combination of anti- VEGF- A therapy with EGFR TKIs to 
VEGFR2 blockade combined with various molecular targeted agents 
in oncogene- driven NSCLC. We demonstrated that the anti- mouse 
VEGFR2 antibody DC101 enhanced the anti- tumor effects of mo-
lecular targeted agents in mice bearing ALK- , ROS1- , or EGFR- altered 
NSCLC.
Although the synergistic effects of anti- VEGF- A or anti- VEGFR2 
antibodies with EGFR TKIs have been demonstrated in multiple clin-
ical and preclinical studies,10,11,14- 16 the precise underlying mecha-
nisms are unclear. In this study, we performed CD31 immunostaining 
and showed that the combination of molecular targeted agents and 
VEGFR2 blockade with DC101 profoundly inhibited tumor angio-
genesis. As DC101 can act on mouse vessels but not on implanted 
human cancer cells, the enhanced anti- tumor effects of the combi-
nation therapy in the xenograft mouse models were attributed to 
the antiangiogenic effects of VEGFR2 blockade.
In contrast with the well established roles of VEGFR2 signaling 
in angiogenesis, the cell- intrinsic effects of anti- VEGFR2 therapy on 
cancer cells are less clear. Cancer cells express VEGFRs, and auto-
crine VEGF/VEGFR signaling promotes cancer cell growth, survival, 
migration, and invasion.17 However, the relevance of VEGFR sig-
naling in oncogene- driven NSCLC was unknown. To determine the 
cell- intrinsic effects of anti- VEGFR2 therapy on oncogene- driven 
NSCLC cells, we treated different human NSCLC cell lines with an 
anti- human VEGFR2 antibody, ramucirumab, in vitro. The combina-
tion of ramucirumab with molecular targeted agents potentiated the 
antiproliferative effects of these agents, implying a cell- intrinsic role 
of VEGFR2 signaling in oncogene- driven NSCLC.
VEGF- A expression is induced by various factors, including 
EGFR18, however a possible association between VEGFR signaling and 
ALK, or ROS- 1 signaling, in lung cancer remains elusive. In this study, 
we demonstrated that oncogenic signaling pathways influenced the 
expression of VEGF- A and VEGFR2; VEGF- A was highly expressed in 
EGFR/ALK/ROS1- driven NSCLC cells (Figure 5A) and was induced by 
forced overexpression of mutant EGFR (Figure 5B). These data high-
lighted the fact that oncogenic signaling pathways can induce VEGFR2 
pathway activation. Of note, the VEGFR2 mRNA levels were also el-
evated in EGFR/ALK/ROS1- driven NSCLC cells (Figure 6A) and were 
further increased after treatment with molecular targeted agents 
(Figure 6C), whereas the VEGF- A levels decreased transiently after 
treatment (Figure 5C). These data implied that the VEGFR2 signaling 
axis plays an important role in oncogene- driven lung cancers; VEGFR2 
levels would increase as a complemental response to the transient de-
crease in VEGF- A levels induced by inhibition of oncogene signaling.
Another research group has investigated the therapeutic effects 
of a similar treatment strategy on oncogene- driven cancer. In their 
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F I G U R E  6   VEGFR2 is highly expressed in oncogene- driven NSCLC cells. A, qRT- PCR of VEGFR2 in PC- 9, H3255, ABC- 11, H3122, HCC78, 
and ABC- 20 cells. GAPDH was used as the reference gene. Data are presented as means ± standard error. B, Clinical specimens of tumors 
bearing EGFR mutations exhibited higher levels of VEGFR2 expression than did EGFR- wild- type tissues, as revealed by immunostaining. 
C, Increased VEGFR2 expression induced by treatment with erlotinib, alectinib, or crizotinib in accordance with qRT- PCR. PC- 9, ABC- 11, 
and ABC- 20 cells were treated with erlotinib (100 nmol/L), alectinib (100 nmol/L), or crizotinib (1 μmol/L), respectively, for 24 h. Data are 

























































































































































































































     |  11WATANABE ET Al.
study, they inhibited oncogenic drivers in combination with target-
ing the VEGF co- receptor neuropilin- 1.19,20 This combination ther-
apy exerted potent anti- tumor effects in vitro in oncogene- driven 
melanoma and breast cancer cells,21 further supporting our findings 
regarding the importance of VEGFR2 as a therapeutic target in com-
bination with molecular targeted agents.
In conclusion, we found that VEGFR2 blockade augmented the anti- 
tumor effects of molecular targeted agents in oncogene- driven NSCLC, 
particularly in EGFR/ALK/ROS1- driven NSCLC. We also identified two 
mechanisms underlying the synergistic effects of anti- VEGFR2 therapy 
with molecular targeted agents. VEGFR2 blockade not only inhibited 
tumor angiogenesis but also exerted direct antiproliferative effects on 
F I G U R E  7   VEGFR2 blockade augments the anti- tumor effects of TKIs in mice bearing PC- 9 tumors. A, Mice bearing PC- 9 tumors 
were treated with erlotinib, erlotinib plus DC101, erlotinib plus ramucirumab, or triplet therapy. Erlotinib (30 mg/kg/d) was administered 
intraperitoneally 5 times weekly. DC101 and ramucirumab (10 mg/kg/d) were administered intraperitoneally twice weekly. B, Body weight of 
mice bearing PC- 9 tumors. C, Immunohistochemical staining of CD31 in mice bearing PC- 9 tumors. Scale bars: 100 μm. D, Number of CD31- 
positive blood vessels in tumors treated with the indicated drugs. Each bar indicates the average number of CD31- positive blood vessels in 5 
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cancer cells. Thus, combination therapy with ramucirumab and molec-
ular targeted agents could serve as a promising treatment strategy for 
ALK- or ROS1- rearranged NSCLC, in addition to EGFR- mutant NSCLC.
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